Immunogenicity using a combination of DNA and vaccinia virus vector vaccines
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsGenoveffa Franchini, Zdenek Hel, George Pavlakis
Life of this patent
Estimating the term…
Abstract
This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immune response. The present invention further provides a particularly effective vaccine regimen comprising a DNA vaccine used in combination with a poxvirus virus, especially NYVAC or ALVAC.
Claims14
A method of potentiating a CD8+ response to human immunodeficiency virus-1 (HIV-1) epitopes in a human comprising:
- administering an expression vector encoding HIV-1 Gag, Pol, Pro, Tat, Nef, Rev, Vif, Vpr or Env antigens;
- and
- administering a recombinant NYVAC pox virus encoding the same antigens encoded by the expression vector;
- wherein the expression vector and the recombinant pox virus enter the cells of the human and intracellularly produce HIV peptides that are presented on the cell's MHC class I molecules in an amount sufficient to stimulate a CD8+ response, and further, wherein administration of the combination of the expression vector and the recombinant pox virus potentiates the immune response compared to administration of either the expression vector or the recombinant pox virus by itself.
A method of reducing viral load in a mammal that may be infected with an immunodeficiency virus, comprising:
- administering to the mammal an expression vector that expresses encoded immunodeficiency virus Gag, Pol and Env antigens;
- and
- later administering to the mammal a recombinant NYVAC pox virus encoding said antigens;
- wherein the expression vector and the recombinant pox virus enter the cells of the mammal and intracellularly produce said antigens, and
- wherein admininstration of the combination of the expression vector and the recombinant pox virus reduces the viral load more than administration of either the expression vector or the recombinant pox virus by itself.
Dependencies are inferred from the claim text.